The pathologic paradigm for renal progression is advancing tubulointerstitial fibrosis.
Whereas mechanisms underlying fibrogenesis have grown in scope and understanding in
recent decades, effective human treatment to directly halt or even reverse fibrosis remains
elusive. Here, we examine key features mediating the molecular and cellular basis of
tubulointerstitial fibrosis and highlight new insights that may lead to novel therapies. How to
prevent chronic kidney disease from progressing to renal failure awaits even deeper …